QDEL vs. NEOG, LNTH, NTLA, MYGN, CLDX, TXG, ROIV, BLCO, OGN, and OPCH
Should you be buying QuidelOrtho stock or one of its competitors? The main competitors of QuidelOrtho include Neogen (NEOG), Lantheus (LNTH), Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), Celldex Therapeutics (CLDX), 10x Genomics (TXG), Roivant Sciences (ROIV), Bausch + Lomb (BLCO), Organon & Co. (OGN), and Option Care Health (OPCH). These companies are all part of the "medical" sector.
QuidelOrtho vs.
QuidelOrtho (NASDAQ:QDEL) and Neogen (NASDAQ:NEOG) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.
QuidelOrtho received 102 more outperform votes than Neogen when rated by MarketBeat users. Likewise, 67.77% of users gave QuidelOrtho an outperform vote while only 58.54% of users gave Neogen an outperform vote.
QuidelOrtho has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Comparatively, Neogen has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500.
QuidelOrtho currently has a consensus price target of $123.83, suggesting a potential upside of 40.94%. Neogen has a consensus price target of $20.00, suggesting a potential upside of 8.17%. Given QuidelOrtho's stronger consensus rating and higher probable upside, analysts clearly believe QuidelOrtho is more favorable than Neogen.
In the previous week, QuidelOrtho had 2 more articles in the media than Neogen. MarketBeat recorded 7 mentions for QuidelOrtho and 5 mentions for Neogen. QuidelOrtho's average media sentiment score of 0.88 beat Neogen's score of 0.30 indicating that QuidelOrtho is being referred to more favorably in the media.
QuidelOrtho has higher revenue and earnings than Neogen. QuidelOrtho is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.
95.2% of QuidelOrtho shares are owned by institutional investors. Comparatively, 97.1% of Neogen shares are owned by institutional investors. 2.7% of QuidelOrtho shares are owned by insiders. Comparatively, 0.7% of Neogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
QuidelOrtho has a net margin of 16.80% compared to Neogen's net margin of -2.57%. QuidelOrtho's return on equity of 20.45% beat Neogen's return on equity.
Summary
QuidelOrtho beats Neogen on 15 of the 19 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding QDEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
QuidelOrtho Competitors List
